JP2011105739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011105739A5 JP2011105739A5 JP2011011811A JP2011011811A JP2011105739A5 JP 2011105739 A5 JP2011105739 A5 JP 2011105739A5 JP 2011011811 A JP2011011811 A JP 2011011811A JP 2011011811 A JP2011011811 A JP 2011011811A JP 2011105739 A5 JP2011105739 A5 JP 2011105739A5
- Authority
- JP
- Japan
- Prior art keywords
- parathyroid hormone
- preparation according
- prevention
- concentration
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims 7
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims 7
- 102000058004 human PTH Human genes 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- 239000000199 parathyroid hormone Substances 0.000 claims 3
- 229960001319 parathyroid hormone Drugs 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008181 tonicity modifier Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801495A SE9801495D0 (sv) | 1998-04-28 | 1998-04-28 | Protein formulationa |
| SE9801495-4 | 1998-04-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545551A Division JP4733267B2 (ja) | 1998-04-28 | 1999-04-26 | タンパク質製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011105739A JP2011105739A (ja) | 2011-06-02 |
| JP2011105739A5 true JP2011105739A5 (enExample) | 2012-04-12 |
| JP5753692B2 JP5753692B2 (ja) | 2015-07-22 |
Family
ID=20411122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545551A Expired - Lifetime JP4733267B2 (ja) | 1998-04-28 | 1999-04-26 | タンパク質製剤 |
| JP2011011811A Expired - Lifetime JP5753692B2 (ja) | 1998-04-28 | 2011-01-24 | タンパク質製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545551A Expired - Lifetime JP4733267B2 (ja) | 1998-04-28 | 1999-04-26 | タンパク質製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20050209144A1 (enExample) |
| EP (1) | EP1079803B1 (enExample) |
| JP (2) | JP4733267B2 (enExample) |
| KR (1) | KR100579872B1 (enExample) |
| CN (1) | CN1172658C (enExample) |
| AT (1) | ATE273693T1 (enExample) |
| AU (2) | AU766514B2 (enExample) |
| BR (1) | BR9909958A (enExample) |
| CA (1) | CA2329800C (enExample) |
| CY (1) | CY2006006I1 (enExample) |
| DE (3) | DE69919533T2 (enExample) |
| DK (1) | DK1079803T3 (enExample) |
| ES (1) | ES2224637T3 (enExample) |
| FR (1) | FR06C0032I2 (enExample) |
| HK (1) | HK1041218B (enExample) |
| IL (1) | IL139320A (enExample) |
| LU (1) | LU91281I2 (enExample) |
| NL (1) | NL300243I2 (enExample) |
| NZ (1) | NZ508269A (enExample) |
| PT (1) | PT1079803E (enExample) |
| SE (1) | SE9801495D0 (enExample) |
| SI (1) | SI1079803T1 (enExample) |
| WO (1) | WO1999055353A2 (enExample) |
| ZA (1) | ZA200006040B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| BRPI0618469A2 (pt) * | 2005-11-10 | 2011-08-30 | Univ Michigan Tech | hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto |
| US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| CA2664734C (en) | 2006-10-03 | 2023-08-01 | Radius Health, Inc. | Method of drug delivery for bone anabolic protein |
| USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| FR2925333B1 (fr) * | 2007-12-19 | 2012-04-13 | Farid Bennis | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
| JP2009091363A (ja) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Ｐｔｈの安定化水溶液注射剤 |
| CA2782640A1 (en) | 2009-12-07 | 2011-06-16 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| KR101787956B1 (ko) * | 2011-06-07 | 2017-10-18 | 아사히 가세이 파마 가부시키가이샤 | 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법 |
| CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
| RS67458B1 (sr) | 2014-03-28 | 2025-12-31 | Univ Duke | Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena |
| KR102676629B1 (ko) | 2015-04-29 | 2024-06-18 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| CN106309358A (zh) * | 2015-06-29 | 2017-01-11 | 成都金凯生物技术有限公司 | 含有人甲状旁腺激素的药物组合物及其制备方法与用途 |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| CN108333360A (zh) * | 2017-01-19 | 2018-07-27 | 深圳市新产业生物医学工程股份有限公司 | 胃泌素释放肽前体稀释液及其应用和试剂盒 |
| US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
| US20200289621A1 (en) * | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
| CN108159404B (zh) * | 2018-01-05 | 2019-08-27 | 北京博康健基因科技有限公司 | 重组人甲状旁腺激素制剂及其制备方法 |
| CN112423844B (zh) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| JOP20210218A1 (ar) | 2019-02-12 | 2023-01-30 | Radius Pharmaceuticals Inc | عمليات ومركبات |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| DE3935738A1 (de) * | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5744444A (en) * | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
| US5547939A (en) * | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| JP2662842B2 (ja) * | 1991-12-09 | 1997-10-15 | 旭化成工業株式会社 | パラサイロイドホルモンの安定化組成物 |
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| ATE220327T1 (de) * | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | Pulmonale abgabe von aktiven fragmenten des parathormons |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| JPH09157294A (ja) * | 1995-06-15 | 1997-06-17 | Takeda Chem Ind Ltd | 副甲状腺ホルモン誘導体 |
| DE19538687A1 (de) * | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
| JP4053107B2 (ja) * | 1996-02-01 | 2008-02-27 | 中外製薬株式会社 | 血小板減少症の予防剤および治療剤 |
| US5964807A (en) * | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
| DE19733651A1 (de) * | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
-
1998
- 1998-04-28 SE SE9801495A patent/SE9801495D0/xx unknown
-
1999
- 1999-04-26 AT AT99917715T patent/ATE273693T1/de active
- 1999-04-26 WO PCT/CA1999/000376 patent/WO1999055353A2/en not_active Ceased
- 1999-04-26 KR KR1020007012037A patent/KR100579872B1/ko not_active Expired - Lifetime
- 1999-04-26 JP JP2000545551A patent/JP4733267B2/ja not_active Expired - Lifetime
- 1999-04-26 ES ES99917715T patent/ES2224637T3/es not_active Expired - Lifetime
- 1999-04-26 BR BR9909958-6A patent/BR9909958A/pt not_active Application Discontinuation
- 1999-04-26 DE DE69919533T patent/DE69919533T2/de not_active Expired - Lifetime
- 1999-04-26 NZ NZ508269A patent/NZ508269A/en not_active IP Right Cessation
- 1999-04-26 DK DK99917715T patent/DK1079803T3/da active
- 1999-04-26 AU AU35916/99A patent/AU766514B2/en not_active Expired
- 1999-04-26 DE DE122006000057C patent/DE122006000057I2/de active Active
- 1999-04-26 HK HK02102980.6A patent/HK1041218B/zh not_active IP Right Cessation
- 1999-04-26 EP EP99917715A patent/EP1079803B1/en not_active Expired - Lifetime
- 1999-04-26 SI SI9930678T patent/SI1079803T1/xx unknown
- 1999-04-26 PT PT99917715T patent/PT1079803E/pt unknown
- 1999-04-26 CA CA002329800A patent/CA2329800C/en not_active Expired - Lifetime
- 1999-04-26 IL IL139320A patent/IL139320A/en not_active IP Right Cessation
- 1999-04-26 DE DE1999619533 patent/DE122006000057I1/de active Pending
- 1999-04-26 CN CNB998073628A patent/CN1172658C/zh not_active Expired - Lifetime
-
2000
- 2000-10-26 ZA ZA200006040A patent/ZA200006040B/en unknown
-
2004
- 2004-01-16 AU AU2004200156A patent/AU2004200156B2/en not_active Expired
- 2004-11-30 US US10/999,160 patent/US20050209144A1/en not_active Abandoned
-
2006
- 2006-10-17 NL NL300243C patent/NL300243I2/nl unknown
- 2006-10-19 LU LU91281C patent/LU91281I2/fr unknown
- 2006-10-20 FR FR06C0032C patent/FR06C0032I2/fr active Active
- 2006-10-23 CY CY200600006C patent/CY2006006I1/el unknown
-
2011
- 2011-01-24 JP JP2011011811A patent/JP5753692B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2018507914A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2010522242A5 (enExample) | ||
| JP2010504973A5 (enExample) | ||
| BRPI0520082A2 (pt) | formas de dosagem de risedronato | |
| JP2013121983A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| JP2017531033A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2015522603A5 (enExample) | ||
| JP2020524689A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| NO20091644L (no) | Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist | |
| CO6341514A2 (es) | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica | |
| NO20075393L (no) | Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse | |
| PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
| JP2009500045A5 (enExample) | ||
| RU2017114677A (ru) | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество |